Targeting the BRAF pathway in haematological diseases.
Intern Med J
; 53(5): 845-849, 2023 05.
Article
en En
| MEDLINE
| ID: mdl-37222093
ABSTRACT
Since the recognition of BRAF V600E mutations in the majority of cases of hairy cell leukaemia, Erdheim-Chester disease and Langerhans cell histiocytosis, the targeted oral kinase inhibitors dabrafenib and vemurafenib have been adapted for their treatment. Like other targeted agents, these drugs produce high response rates and predictable but unique side effects. Physician familiarity is essential for the effective use of these agents. We review the Australian experience of BRAF/MEK inhibitor therapy in these rare haematological cancers.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Hematológicas
/
Proteínas Proto-Oncogénicas B-raf
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
País/Región como asunto:
Oceania
Idioma:
En
Revista:
Intern Med J
Asunto de la revista:
MEDICINA INTERNA
Año:
2023
Tipo del documento:
Article
País de afiliación:
Australia